{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:10:41Z","timestamp":1792649441371,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Doxycycline post-exposure prophylaxis (Doxy-PEP) reduces the likelihood of Chlamydia and early syphilis by approximately two-thirds. Currently, data on the frequency of Doxy-PEP use in men who have sex with men (MSM) are limited. This study aimed to assess knowledge, attitude towards, and frequency of Doxy-PEP use among MSM in Germany.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a national online survey in Germany from summer to fall 2023, recruiting MSM and transgender women. Participants were invited to complete the online survey through social media, online dating platforms, and print media advertisements with active recruitment and poster advertising in private practices, tertiary outpatient clinics, and MSM community events in Germany.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 438 participants completed the survey and were included in the analysis, and 285 (65.1%) were living with the human immunodeficiency virus (HIV) or taking HIV-pre-exposure prophylaxis (PrEP). Overall, 170 participants (38.8%) had heard of Doxy-PEP, and 275 (62.8%) would consider taking it, but only 32 (7.3%) reported having ever taken Doxy-PEP. The most common reason for a negative attitude towards Doxy-PEP were apprehension about insufficient detailed information, and concerns about antibiotic resistance. Doxy-PEP users were more likely to be on HIV-PrEP, had a higher self-reported risk of bacterial sexually transmitted infections (STIs), and often had a history of bacterial STIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The study demonstrated high awareness and strong interest in Doxy-PEP among MSM in Germany, most of whom were living with HIV or taking HIV-PrEP; however, the actual usage of Doxy-PEP remains low in the summer and fall of 2023.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s15010-024-02321-x","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T09:02:36Z","timestamp":1721725356000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Is doxycycline post-exposure prophylaxis being utilised in Germany? Insights from an online survey among German men who have sex with men"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-8154","authenticated-orcid":false,"given":"Laura","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Baumgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Audebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Noe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Triebelhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Voit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2321_CR1","unstructured":"World Health Organization. Sexually transmitted infections (STIs). 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis). Accessed 27. Apr 2023."},{"key":"2321_CR2","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2021. 2023. https:\/\/www.cdc.gov\/std\/statistics\/2021\/default.htm. Accessed 27. Apr 2023."},{"key":"2321_CR3","unstructured":"Centers for Disease Control and Prevention. CDC Response to Doxy-PEP data presented at 2022 International AIDS Conference. 2022. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2022\/Doxy-PEP-clinical-data-presented-at-2022-AIDS-Conference.html. Accessed 24. Nov 2023."},{"key":"2321_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl Med. 2023;388:1296\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa2211934.","journal-title":"N Engl Med"},{"key":"2321_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"18","author":"J-M Molina","year":"2018","unstructured":"Molina J-M, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18:308\u201317. https:\/\/doi.org\/10.1016\/S1473-3099(17)30725-9.","journal-title":"Lancet Infect Dis"},{"key":"2321_CR6","unstructured":"Robert Koch Institut. Gonokokken-Resistenzsurveillance (Go-Surv-AMR). 2023. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/G\/Gonorrhoe\/GORENET\/GORENET_inhalt.html. Accessed 06. Apr 2023."},{"key":"2321_CR7","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"389","author":"J Stewart","year":"2023","unstructured":"Stewart J, Oware K, Donnell D, et al. Doxycycline Prophylaxis to prevent sexually transmitted infections in women. N Engl Med. 2023;389:2331\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(17)30725-9.","journal-title":"N Engl Med"},{"key":"2321_CR8","unstructured":"Science Media Center Germany gGmbH. Pille danach f\u00fcr sexuell \u00fcbertragbare Krankheiten. 2023. https:\/\/www.sciencemediacenter.de\/alle-angebote\/research-in-context\/details\/news\/pille-danach-fuer-sexuell-uebertragbare-krankheiten\/. Accessed 27. Apr 2023."},{"key":"2321_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1097\/OLQ.0000000000000942","volume":"46","author":"MA Spinelli","year":"2019","unstructured":"Spinelli MA, Scott HM, Vittinghoff E, et al. High interest in doxycycline for sexually transmitted infection postexposure Prophylaxis in a Multicity Survey of men who have sex with men using a social networking application. Sex Transm Dis. 2019;46:e32\u20134. https:\/\/doi.org\/10.1097\/OLQ.0000000000000942.","journal-title":"Sex Transm Dis"},{"key":"2321_CR10","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S2352-3018(18)30210-8","volume":"5","author":"T Carveth-Johnson","year":"2018","unstructured":"Carveth-Johnson T, Stingone C, Nwokolo N, et al. Doxycycline use in MSM taking PrEP. Lancet HIV. 2018;5:e482. https:\/\/doi.org\/10.1016\/S2352-3018(18)30210-8.","journal-title":"Lancet HIV"},{"key":"2321_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/OLQ.0000000000001130","volume":"47","author":"L Fusca","year":"2020","unstructured":"Fusca L, Hull M, Ross P, et al. High interest in Syphilis Pre-exposure and Post-exposure Prophylaxis among Gay, bisexual and other men who have sex with men in Vancouver and Toronto. Sex Transm Dis. 2020;47:224\u201331. https:\/\/doi.org\/10.1097\/OLQ.0000000000001130.","journal-title":"Sex Transm Dis"},{"key":"2321_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/OLQ.0000000000001395","volume":"48","author":"JJ Park","year":"2021","unstructured":"Park JJ, Stafylis C, Pearce DD, et al. Interest, concerns, and attitudes among men who have sex with men and Health Care providers toward prophylactic use of doxycycline against Chlamydia trachomatis infections and Syphilis. Sex Transm Dis. 2021;48:615\u20139. https:\/\/doi.org\/10.1097\/OLQ.0000000000001395.","journal-title":"Sex Transm Dis"},{"key":"2321_CR13","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2352-3018(19)30186-9","volume":"6","author":"EPF Chow","year":"2019","unstructured":"Chow EPF, Fairley CK. Use of doxycycline prophylaxis among gay and bisexual men in Melbourne. Lancet HIV. 2019;6:e568. https:\/\/doi.org\/10.1016\/S2352-3018(19)30186-9. 569.","journal-title":"Lancet HIV"},{"key":"2321_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/sextrans-2019-054325","volume":"96","author":"Y Evers","year":"2020","unstructured":"Evers Y, van Liere G, Dukers-Muijrers N, et al. Use of doxycycline and other antibiotics to prevent STIs among men who have sex with men visiting sexual health clinics in the Netherlands. Sex Transm Infect. 2020;96:550\u20131. https:\/\/doi.org\/10.1136\/sextrans-2019-054325.","journal-title":"Sex Transm Infect"},{"key":"2321_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jiph.2022.07.012","volume":"15","author":"P Ahaus","year":"2022","unstructured":"Ahaus P, Schmidt AJ, Skaletz-Rorowski A, et al. Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. J Infect Public Health. 2022;15:955\u201360. https:\/\/doi.org\/10.1016\/j.jiph.2022.07.012.","journal-title":"J Infect Public Health"},{"key":"2321_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/sextrans-2020-054592","volume":"97","author":"C O\u2019Halloran","year":"2021","unstructured":"O\u2019Halloran C, Croxford S, Mohammed H, et al. Factors associated with reporting antibiotic use as STI prophylaxis among HIV PrEP users: findings from a cross-sectional online community survey, May\u2013July 2019, UK. Sex Transm Infect. 2021;97:429\u201333. https:\/\/doi.org\/10.1136\/sextrans-2020-054592.","journal-title":"Sex Transm Infect"},{"key":"2321_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/OLQ.0b013e31820e64fd","volume":"38","author":"DP Wilson","year":"2011","unstructured":"Wilson DP, Prestage GP, Gray RT, et al. Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis. 2011;38:573\u20139. https:\/\/doi.org\/10.1097\/OLQ.0b013e31820e64fd.","journal-title":"Sex Transm Dis"},{"key":"2321_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","volume":"24","author":"J Ambrosioni","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24:1126\u201336. https:\/\/doi.org\/10.1111\/hiv.13542.","journal-title":"HIV Med"},{"key":"2321_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15282","author":"RN Werner","year":"2023","unstructured":"Werner RN, Schmidt AJ, Potthoff A, et al. Position statement of the German STI Society on the prophylactic use of doxycycline to prevent STIs (Doxy-PEP, Doxy-PrEP). J Dtsch Dermatol Ges. 2023https:\/\/doi.org\/10.1111\/ddg.15282.","journal-title":"J Dtsch Dermatol Ges"},{"key":"2321_CR20","unstructured":"Molina J-M, Bercot B, Assoumou L, ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP. 2023. https:\/\/www.croiconference.org\/abstract\/anrs-174-doxyvac-an-open-label-randomized-trial-to-prevent-stis-in-msm-on-prep\/. Accessed 24. Nov 2023."},{"key":"2321_CR21","doi-asserted-by":"publisher","unstructured":"La Ruche G, Goubard A, Bercot B, et al. Gonococcal infections and emergence of gonococcal decreased susceptibility to cephalosporins in France, 2001 to 2012. Euro Surveill. 2014;19. https:\/\/doi.org\/10.2807\/1560-7917.es2014.19.34.20885.","DOI":"10.2807\/1560-7917.es2014.19.34.20885"},{"key":"2321_CR22","unstructured":"Jansen K, Selb R, Tamminga T. Deutsche Gonokokken-Resistenz- Surveillance (Go-SURV). 2021. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/G\/Gonorrhoe\/GORENET\/GORENET-Bericht_2021.pdf?__blob=publicationFile. Accessed 29. Nov 2023."},{"key":"2321_CR23","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLOS Med. 2017;14:e1002344. https:\/\/doi.org\/10.1371\/journal.pmed.1002344.","journal-title":"PLOS Med"},{"key":"2321_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","volume":"22","author":"WE Abara","year":"2022","unstructured":"Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis. 2022;22:1021\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(21)00812-4.","journal-title":"Lancet Infect Dis"},{"key":"2321_CR25","unstructured":"European AIDS, Treatment Goup. ANRS Doxyvac: final analysis may modify interim results of this trial assessing the effectiveness of meningococcal B vaccination in preventing gonococcal infections. 2023. https:\/\/www.eatg.org\/hiv-news\/anrs-doxyvac-final-analysis-may-modify-interim-results-of-this-trial-assessing-the-effectiveness-of-meningococcal-b-vaccination-in-preventing-gonococcal-infections\/. Accessed 7. Dec 2023."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02321-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T19:49:49Z","timestamp":1739476189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02321-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2321"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02321-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (approval No. 2023-391-S-KK). It was conducted in accordance with the principles of the Declaration of Helsinki. Before participating in the survey, participants declared consent to the privacy policy and further use of anonymised data after completing the online survey. Written informed consent was not obtained from participants; instead, they received participant information and privacy policy and declared consent for the further use of anonymised data after completing the online survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"JS reports grants, personal fees, and non-financial support from AbbVie, Gilead Sciences, Janssen-Cilag, GSK\/ViiV Healthcare, and MSD; Dr. Falk Pharma GmbH, Diasorin, Deutsche Forschungsgemeinschaft and the Central Innovation Programme for small- and medium-sized enterprises outside the submitted work. CDS reports grants, personal fees from AstraZeneca; personal fees and non-financial support from BBraun Melsungen; personal fees from BioNtech; grants, personal fees and non-financial support from Gilead Sciences; grants and personal fees from Janssen-Cilag; personal fees from Eli Lilly; personal fees from Formycon; personal fees from Pfizer; personal fees from Roche; other from Apeiron; grants and personal fees from MSD; grants from Cepheid; personal fees from GSK; personal fees from Molecular partners; personal fees from Pfizer; other from Eli Lilly; personal fees from SOBI during the conduct of the study; personal fees from AbbVie; personal fees from MSD; personal fees from Synairgen; personal fees from Shionogi; grants and personal fees from ViiV Healthcare, outside the submitted work. JE reports non-financial support from Gilead Sciences, ViiV Healthcare, and Pfizer. FV reports personal fees and non-financial support from Gilead Sciences and ViiV Healthcare, and grants from MSD and B. Braun Melsungen AG outside of the submitted work. CB reports personal honoraria for lectures and\/or consultancies from AbbVie, Astra Zeneca, Bavarian Nordic, Gilead Sciences, Janssen Pharmaceuticals, MSD, Pfizer and ViiV Healthcare as well as institutional funding from Deutsche Leberstiftung, DZIF, Hector Stiftung and NEAT-ID.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}}]}}